Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ARC1779 in Acute Myocardial Infarction Patients Undergoing PCI
2007-002547-25Phase 2Terminated
- Sponsor
- Archemix Corp.
- Start
- Jul 2007
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of egaptivon pegol in myocardial infarction (MI) and acute coronary syndrome (ACS) (2 arms), sponsored by Archemix Corp. Primary endpoints: Safety parameters and Ischemic phenomena related to microvascular coronary thrombosis and thromboembolism. Started Jul 2007; status: terminated.
02
Drugs
egaptivon pegol
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2007-002547-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002547-25.